Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhi…
| Métrica | APLM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -1107.3% | -39.2% | -1068.1% |
| ROA | -411.2% | -30.9% | -380.2% |
| Current Ratio | 1.39 | 2.73 | -1.34 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -411.2% | — |
| ✗Flujo de caja operativo positivo | −$29M | −$43M |
| ✗Rentabilidad sobre activos al alza | -411.2% | -311.6% |
| ✓Caja operativa/activos supera al ROA | -219.4% | ROA -411.2% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 1.39 | 2.95 |
| ✗Sin aumentar el nº de acciones | 1M | — |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.00 | 0.00 |
| Calidad del negocio | FY24 |
|---|---|
| ✓Deuda neta/EBITDA < 3x | Caja neta |
Apollomics Inc. cotiza a 21.10 USD y tiene una capitalización bursátil de $62M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud